Biorithm, a Singapore-based startup, is developing Femom, a home-use device that allows women to monitor their pregnancy by tracking maternal and fetal heart rates. This innovation aims to empower women with accessible care, addressing the high rates of maternal and infant mortality, particularly in lower-income countries. With recent funding of $3.5 million, Biorithm plans to expand its technology in the U.S. and Southeast Asia, highlighting a shift in the funding landscape for women's health initiatives.